Petco Reports Strong Q1 2026 Results, Exceeding Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2026
0mins
Source: PRnewswire
- Sales Growth Resurgence: Petco reported Q1 2026 net sales of $1.497 billion, reflecting a 0.2% year-over-year increase, marking a return to positive comparable sales growth that validates the effectiveness of its 'Reach for the Sky' strategy and boosts investor confidence.
- Profitability Improvement: The adjusted EBITDA for Q1 reached $97.3 million, an 8.5% increase from the previous year, demonstrating significant enhancements in operational efficiency and cost control, which support sustainable profit growth.
- Financial Outlook Reaffirmed: Petco reaffirmed its full-year 2026 net sales outlook of flat to up 1.5%, with Q2 net sales expected to grow approximately 0.3% year-over-year, indicating confidence in future performance and stability.
- Leverage Ratio Target: The company aims to reduce its leverage ratio to 2x, reflecting its commitment to financial management and risk control, which is intended to enhance long-term financial health and investor trust.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WOOF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WOOF
Wall Street analysts forecast WOOF stock price to rise
7 Analyst Rating
2 Buy
4 Hold
1 Sell
Hold
Current: 2.830
Low
3.00
Averages
3.55
High
4.53
Current: 2.830
Low
3.00
Averages
3.55
High
4.53
About WOOF
Petco Health and Wellness Company, Inc. is a pet health and wellness company focused on improving the lives of pets, pet parents, and its own Petco partners. It offers pet parents a full spectrum of product choices with products to address ongoing humanization and premiumization trends in the market. It integrates its product offering with its services business, building on the foundation of treating the whole pet, including their physical, mental and social well-being. Its service offering includes veterinary care, grooming, and training. It operates a network of full-service, general practice veterinary hospitals complemented by prescription and insurance offerings. It operates more than 1,500 pet care centers across the United States, Mexico and Puerto Rico and a growing network of on-site veterinary hospitals and mobile veterinary clinics. It offers a complete pet health and wellness ecosystem accessible through its pet care centers and digitally at petco.com and on the Petco app.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Chewy Stock Continues Decline Post Earnings Report
- Earnings Highlights: Chewy reported fiscal Q1 2026 net sales of $3.36 billion, a 7.7% year-over-year increase, with net income rising to $94.8 million, up 52% from last year, indicating improvements in revenue and margins.
- Market Reaction: Despite strong earnings, Chewy's stock fell 4.75% post-report due to cautious guidance on future sales, leading to a 43% decline this year, reflecting market concerns over macroeconomic pressures.
- Analyst Rating Adjustments: Several analysts have lowered their price targets for Chewy, with Morgan Stanley reducing its target from $43 to $42, highlighting economic concerns, while Bank of America maintained a 'Buy' rating but cut its target to $31, indicating weakened market confidence.
- Future Outlook: Chewy projects full-year sales between $13.4 billion and $13.55 billion, with growth rates of 6.3% to 7.5%, but anticipates customer additions at the lower end of previous estimates, suggesting challenges in customer acquisition that may impact future growth potential.
See More
Chewy Shares Decline as Analysts Cut Forecasts Amid Economic Concerns
- Customer Acquisition Warning: Chewy's management has indicated that net customer additions for the year will be at the lower end of the 150,000 to 250,000 range, reflecting a conservative outlook on the consumer environment, which could hinder future sales growth and market share.
- Financial Performance vs. Market Reaction: Despite reporting quarterly net sales of $3.36 billion, a 7.7% increase year-over-year, and net income rising from $62.4 million to $94.8 million, Chewy's stock price has declined due to uncertainty about future growth, indicating market concerns.
- Analyst Downgrades: Several analysts have lowered their price targets for Chewy, with Morgan Stanley reducing its target from $43 to $42 due to worries about the macroeconomic environment, while Bank of America cut its target from $33 to $31, reflecting a lack of market confidence.
- Strategic Investments and Challenges: Chewy plans to operate 60 veterinary clinics by year-end and leverage artificial intelligence to save at least $50 million in costs; however, management warns that inflation and rising interest rates will continue to squeeze potential customers' budgets, impacting business growth.
See More
Market Faces Pressure from Rates and Oil Prices
- Market Pressure Intensifies: The market is under increasing pressure due to rising interest rates and elevated oil prices, particularly amid a wave of new stock offerings that require investors to sell existing shares to participate, leading to declines in major indexes.
- Employment Report Impact: A stronger-than-expected jobs report has pushed Treasury yields higher, diminishing hopes for near-term rate cuts and further exacerbating market uncertainty, leaving investors concerned about future economic prospects.
- Divergent Tech Stock Performance: With Apple's Worldwide Developers Conference approaching, despite questions surrounding its AI strategy, Cramer believes the company's cautious approach to AI infrastructure spending has proven wise, resulting in its stock outperforming other large tech companies.
- Upcoming SpaceX IPO: As SpaceX is expected to debut on the Nasdaq on June 12, Cramer urges investors to quickly raise the necessary funds to participate in the offering, arguing that the market may struggle to advance as long as new stock pressures exist.
See More
Market Faces Pressure from Rising Rates and Oil Prices
- Market Pressure Factors: Jim Cramer warns that the combination of rising interest rates and elevated oil prices could continue to pressure the market, especially with a wave of upcoming AI-related stock offerings that investors must navigate cautiously.
- Major Index Performance: Following a stronger-than-expected jobs report that pushed Treasury yields higher, all three major indexes closed lower, indicating a diminished hope for near-term rate cuts and impacting investor sentiment negatively.
- Upcoming Earnings Reports: Cramer highlights key earnings reports on the horizon, including Apple's Worldwide Developers Conference, suggesting that Apple's decision to refrain from aggressive AI infrastructure spending may prove wise and could influence its stock performance.
- Impact of SpaceX IPO: Cramer anticipates that SpaceX will debut on the Nasdaq on June 12, urging investors to raise the necessary funds to participate, arguing that the market may struggle to advance until new stock offerings are addressed.
See More
Alnylam Partners with Inceptive in AI Collaboration
- Strategic Collaboration: Alnylam Pharmaceuticals has entered into a strategic AI partnership with Inceptive Nucleics valued at up to $2 billion, aiming to leverage Inceptive's generative AI models to accelerate the discovery of RNA interference therapeutics, thereby enhancing its competitive edge in the biopharmaceutical sector.
- Market Rebound: Blackstone's shares rose 8% despite the firm limiting withdrawals from its Private Credit fund, indicating investor confidence as the stock is poised to end a three-day losing streak, reflecting a positive sentiment towards asset management firms.
- Stock Volatility: Broadcom's shares tumbled nearly 15% after reporting second-quarter revenue of $22.19 billion, falling short of the $22.27 billion expected by analysts, although CEO Hock Tan reiterated the company's fiscal year 2027 revenue guidance for AI chips to exceed $100 billion, raising concerns about future growth prospects.
- Healthcare Outlook: UnitedHealth's stock climbed 5% following an upgrade from Bank of America from neutral to buy, citing improving medical cost trends and supportive near-term data points that are expected to favorably impact second-quarter earnings, reflecting optimism in the health insurance sector.
See More
Broadcom's Revenue Miss Leads to 15% Stock Drop
- Broadcom's Revenue Miss: Broadcom reported fiscal Q2 revenue of $22.19 billion, falling short of the $22.27 billion expected by analysts, resulting in a 15% stock drop, marking its first revenue miss since December 2024, raising concerns about future growth prospects.
- Semiconductor Stocks Decline: Following Broadcom's disappointing results, shares of AI semiconductor companies fell, with Micron Technology down 6%, Super Micro Computer down 7%, Intel down 4%, and AMD down nearly 5%, reflecting a pessimistic sentiment towards the semiconductor sector's outlook.
- Five Below's Mixed Signals: Despite Five Below's forecast of Q2 revenue between $1.18 billion and $1.2 billion, exceeding the $1.15 billion estimate, its stock fell nearly 11%, indicating investor concerns about the overall retail sector's performance.
- CrowdStrike's Weak Guidance: CrowdStrike anticipates Q2 revenue around $1.44 billion, slightly above the $1.3 billion estimate, but its stock dropped 10%, suggesting skepticism about its growth potential amid lackluster guidance.
See More
Chewy Stock Continues Decline Post Earnings Report
- Earnings Highlights: Chewy reported fiscal Q1 2026 net sales of $3.36 billion, a 7.7% year-over-year increase, with net income rising to $94.8 million, up 52% from last year, indicating improvements in revenue and margins.
- Market Reaction: Despite strong earnings, Chewy's stock fell 4.75% post-report due to cautious guidance on future sales, leading to a 43% decline this year, reflecting market concerns over macroeconomic pressures.
- Analyst Rating Adjustments: Several analysts have lowered their price targets for Chewy, with Morgan Stanley reducing its target from $43 to $42, highlighting economic concerns, while Bank of America maintained a 'Buy' rating but cut its target to $31, indicating weakened market confidence.
- Future Outlook: Chewy projects full-year sales between $13.4 billion and $13.55 billion, with growth rates of 6.3% to 7.5%, but anticipates customer additions at the lower end of previous estimates, suggesting challenges in customer acquisition that may impact future growth potential.
See More
Chewy Shares Decline as Analysts Cut Forecasts Amid Economic Concerns
- Customer Acquisition Warning: Chewy's management has indicated that net customer additions for the year will be at the lower end of the 150,000 to 250,000 range, reflecting a conservative outlook on the consumer environment, which could hinder future sales growth and market share.
- Financial Performance vs. Market Reaction: Despite reporting quarterly net sales of $3.36 billion, a 7.7% increase year-over-year, and net income rising from $62.4 million to $94.8 million, Chewy's stock price has declined due to uncertainty about future growth, indicating market concerns.
- Analyst Downgrades: Several analysts have lowered their price targets for Chewy, with Morgan Stanley reducing its target from $43 to $42 due to worries about the macroeconomic environment, while Bank of America cut its target from $33 to $31, reflecting a lack of market confidence.
- Strategic Investments and Challenges: Chewy plans to operate 60 veterinary clinics by year-end and leverage artificial intelligence to save at least $50 million in costs; however, management warns that inflation and rising interest rates will continue to squeeze potential customers' budgets, impacting business growth.
See More
Market Faces Pressure from Rates and Oil Prices
- Market Pressure Intensifies: The market is under increasing pressure due to rising interest rates and elevated oil prices, particularly amid a wave of new stock offerings that require investors to sell existing shares to participate, leading to declines in major indexes.
- Employment Report Impact: A stronger-than-expected jobs report has pushed Treasury yields higher, diminishing hopes for near-term rate cuts and further exacerbating market uncertainty, leaving investors concerned about future economic prospects.
- Divergent Tech Stock Performance: With Apple's Worldwide Developers Conference approaching, despite questions surrounding its AI strategy, Cramer believes the company's cautious approach to AI infrastructure spending has proven wise, resulting in its stock outperforming other large tech companies.
- Upcoming SpaceX IPO: As SpaceX is expected to debut on the Nasdaq on June 12, Cramer urges investors to quickly raise the necessary funds to participate in the offering, arguing that the market may struggle to advance as long as new stock pressures exist.
See More
Market Faces Pressure from Rising Rates and Oil Prices
- Market Pressure Factors: Jim Cramer warns that the combination of rising interest rates and elevated oil prices could continue to pressure the market, especially with a wave of upcoming AI-related stock offerings that investors must navigate cautiously.
- Major Index Performance: Following a stronger-than-expected jobs report that pushed Treasury yields higher, all three major indexes closed lower, indicating a diminished hope for near-term rate cuts and impacting investor sentiment negatively.
- Upcoming Earnings Reports: Cramer highlights key earnings reports on the horizon, including Apple's Worldwide Developers Conference, suggesting that Apple's decision to refrain from aggressive AI infrastructure spending may prove wise and could influence its stock performance.
- Impact of SpaceX IPO: Cramer anticipates that SpaceX will debut on the Nasdaq on June 12, urging investors to raise the necessary funds to participate, arguing that the market may struggle to advance until new stock offerings are addressed.
See More
Alnylam Partners with Inceptive in AI Collaboration
- Strategic Collaboration: Alnylam Pharmaceuticals has entered into a strategic AI partnership with Inceptive Nucleics valued at up to $2 billion, aiming to leverage Inceptive's generative AI models to accelerate the discovery of RNA interference therapeutics, thereby enhancing its competitive edge in the biopharmaceutical sector.
- Market Rebound: Blackstone's shares rose 8% despite the firm limiting withdrawals from its Private Credit fund, indicating investor confidence as the stock is poised to end a three-day losing streak, reflecting a positive sentiment towards asset management firms.
- Stock Volatility: Broadcom's shares tumbled nearly 15% after reporting second-quarter revenue of $22.19 billion, falling short of the $22.27 billion expected by analysts, although CEO Hock Tan reiterated the company's fiscal year 2027 revenue guidance for AI chips to exceed $100 billion, raising concerns about future growth prospects.
- Healthcare Outlook: UnitedHealth's stock climbed 5% following an upgrade from Bank of America from neutral to buy, citing improving medical cost trends and supportive near-term data points that are expected to favorably impact second-quarter earnings, reflecting optimism in the health insurance sector.
See More
Broadcom's Revenue Miss Leads to 15% Stock Drop
- Broadcom's Revenue Miss: Broadcom reported fiscal Q2 revenue of $22.19 billion, falling short of the $22.27 billion expected by analysts, resulting in a 15% stock drop, marking its first revenue miss since December 2024, raising concerns about future growth prospects.
- Semiconductor Stocks Decline: Following Broadcom's disappointing results, shares of AI semiconductor companies fell, with Micron Technology down 6%, Super Micro Computer down 7%, Intel down 4%, and AMD down nearly 5%, reflecting a pessimistic sentiment towards the semiconductor sector's outlook.
- Five Below's Mixed Signals: Despite Five Below's forecast of Q2 revenue between $1.18 billion and $1.2 billion, exceeding the $1.15 billion estimate, its stock fell nearly 11%, indicating investor concerns about the overall retail sector's performance.
- CrowdStrike's Weak Guidance: CrowdStrike anticipates Q2 revenue around $1.44 billion, slightly above the $1.3 billion estimate, but its stock dropped 10%, suggesting skepticism about its growth potential amid lackluster guidance.
See More
